The
price will be more expensive than prior COVID-19 antibodies, reflecting its
target to critically ill patients who are hospitalized.
Normal
0
false
false
false
EN-US
X-NONE
X-NONE
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:"";
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin-top:0in;
mso-para-margin-right:0in;
mso-para-margin-bottom:8.0pt;
mso-para-margin-left:0in;
line-height:107%;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:"Calibri",sans-serif;
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;}
InflaRx received an EUA from the FDA for Gohibic • Source: Shutterstock
InflaRx N.V. anticipates seeing commercial sales toward the second half of the year of Gohibic (vilobelimab) following the drug’s emergency use authorization (EUA) from the US Food and Drug Administration for critically ill COVID-19 patients. The company also expects the anti-inflammatory mechanism could open up a longer-term opportunity in other inflammatory indications.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
There was a reduction in the rate of expansion of the pharma pipeline last year but 2024 also saw another welcome increase in the number of drug candidates in Phase III following years of stagnation.
Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.
Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.
